Tonix Pharmaceuticals Holding Corp TNXP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026
-
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
-
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer
-
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
-
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
-
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
-
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
Trading Information
- Previous Close Price
- $6.42
- Day Range
- $6.02–6.56
- 52-Week Range
- $6.01–20.58
- Bid/Ask
- $6.06 / $6.07
- Shares Outstanding
- 17.15M
- Market Cap
- $103.59M
- Volume/Avg
- 935,463 / 606,818
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.65
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 142
- Website
- https://www.tonixpharma.com
Valuation
|
Metric
|
TNXP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.46 |
Price/Sales | 2.65 |
Price/Cash Flow | — |
Price/Earnings
TNXP
Financial Strength
|
Metric
|
TNXP
|
|---|---|
Quick Ratio | 6.22 |
Current Ratio | 6.61 |
Interest Coverage | — |
Quick Ratio
TNXP
Profitability
|
Metric
|
TNXP
|
|---|---|
Return on Assets (Normalized) | −62.37% |
Return on Equity (Normalized) | −70.09% |
Return on Invested Capital (Normalized) | −72.22% |
Return on Assets
TNXP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|nc%@$&< | LOCK|jRTCg | $127B | |||
| Moderna Inc
MRNA
| LOCK|#J<l!y! | LOCK|$< | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|y^TT<$ | LOCK|!&P> | $81B | |||
| argenx SE ADR
ARGX
| LOCK|Sz!&g>? | LOCK|S$< | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|@@<<vsn | LOCK|RB | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|?L&Z?@ | LOCK|^hvj | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<<>#Mf@T | LOCK|&xnY | $27B | |||
| Incyte Corp
INCY
| LOCK|Hb>$M&n | LOCK|n% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|#hn#kfY | LOCK|j>? | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|kQT?lfK | LOCK|lfg | $14B |
United States